Last reviewed · How we verify
PA — Competitive Intelligence Brief
marketed
Visual cycle modulator / Retinoid analog
Ophthalmology
Small molecule
Live · refreshed every 30 min
Target snapshot
PA (PA) — Fovea Pharmaceuticals SA. PA is a prodrug that is converted to its active form to modulate retinal function and treat vision disorders.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| PA TARGET | PA | Fovea Pharmaceuticals SA | marketed | Visual cycle modulator / Retinoid analog |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Visual cycle modulator / Retinoid analog class)
- Fovea Pharmaceuticals SA · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- PA CI watch — RSS
- PA CI watch — Atom
- PA CI watch — JSON
- PA alone — RSS
- Whole Visual cycle modulator / Retinoid analog class — RSS
Cite this brief
Drug Landscape (2026). PA — Competitive Intelligence Brief. https://druglandscape.com/ci/pa. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing